BioAlliance Pharma SA, the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced the grant of its main patent on the Lauriad® technology in Europe.
124569
BioAlliance Pharma announces the
88710
Nanoviricides completes a number of financing activities
91515
Pfizer gets the approval
126233
Astex achieves milestones in drug discovery collaboration
54747
Biorefining plant earns honors
37199
Bionovo (bnvi) to present positive results from phase 2 trial of Menerba
134688
Avesthagen scouting for partners for bioactive ingredients
143014
StatoilHydro granted consent to use Volve
155748
Drug company stands to benefit from legislation
157784
BioElectronics announces revolutionary device for treatment of
88480
Mayo Clinic partnership to advance personalized medicine
96310
Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia
138387
Scientists make breakthrough in plant medicine production
80180
Novartis buys rights to new antibiotic
36114
European Commission approves labelling update for REYATAZ® (atazanavir sulfate) in pregnant women living with HIV
166448
SRC receives patent
85377
Phagenesis secures £6m of funding